DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR GLIMEPIRIDE
Clinical Trials for Glimepiride
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00032487 | Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) | Completed | National Eye Institute (NEI) | Phase 3 | This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications. |
NCT00032487 | Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) | Completed | SmithKline Beecham | Phase 3 | This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications. |
NCT00032487 | Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) | Completed | VA Office of Research and Development | Phase 3 | This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications. |
NCT00095030 | Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone | Completed | Merck Sharp & Dohme Corp. | Phase 3 | The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied. |
Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Glimepiride
Clinical Trial Locations for Glimepiride
Trials by Country
Clinical Trial Progress for Glimepiride
Clinical Trial Phase
Clinical Trial Sponsors for Glimepiride
Sponsor Name